Search results for "Fingerstick"

showing 3 items of 3 documents

Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observat…

2021

While data on the efficacy and safety of continuous glucose monitoring (CGM) exist across a broad age spectrum, it is limited in very young children with type 1 diabetes (T1D). We aimed to assess real-world data in this high-risk population, focusing on glycemic variability and metrics beyond HbA1c. A 12-month multi-national, prospective, observational, registry-based cohort study in children with T1D aged 1-7 years compared glucose control using real-time CGM and using fingerstick blood glucose monitoring (BGM) alone. The prespecified primary endpoint was a difference in coefficient of variation (CV) between the CGM users and BGM-only cohort. Among 227 individuals using insulin pumps (42% …

Insulin pumpBlood GlucosePediatricsmedicine.medical_specialtyendocrine system diseasesFingerstickEndocrinology Diabetes and MetabolismPopulationChildren; Continuous glucose monitoring; Insulin pump; Toddlers; Type 1 diabetesCohort StudiesHDE END PEDEndocrinologyInsulin Infusion SystemsInternal MedicinemedicineHumansHypoglycemic AgentsInsulinInsulin pumpeducationChildChildrenContinuous glucose monitoringchildren; continuous glucose monitoring; insulin pump; toddlers; type 1 diabetesGlycemicBlood glucose monitoringGlycated HemoglobinToddlerseducation.field_of_studyType 1 diabetesmedicine.diagnostic_testEndocrinology; Metabolismbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesDiabetes type 1medicine.diseaseType 1 diabetesDiabetes Mellitus Type 1GlucoseChild PreschoolCohortbusinessCohort studyDiabetes Obesity & Metabolism
researchProduct

Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents

2022

6 páginas, 2 figuras, 3 tablas. Se puede acceder al texto completo de este artículo desde PubMedCentral: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490129 . Los datos de investigación utilizados en el mismo, se encuentran disponibles en: https://doi.org/10.1016/j.cmi.2021.09.031.

MaleMicrobiology (medical)medicine.medical_specialtyCOVID-19 VaccinesSARS-CoV-2-S antibodiesFingerstickSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Nursing home residentsCD8-Positive T-LymphocytesAntibodies ViralImmune systemComirnaty®COVID-19 vaccineInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overVenipuncturebiologybusiness.industrySARS-CoV-2COVID-19General MedicineNursing HomesVaccinationInfectious Diseasesbiology.proteinFemaleOriginal ArticleAntibodybusinessCD8
researchProduct

Point‐of‐care HCV RNA testing in the setting of DAA therapy: HCV‐FiS (HEpatitis C Virus Fingerstick Study)

2019

HCV-RNA assessment during therapy with Direct-Acting Antiviral (DAA) regimens still relies on assays requiring blood collection and transport to a specialised laboratory, which may compromise linkage to care. GeneXpert-HCV Viral Load (GXHVL) (Cepheid) is a plasma-based assay used at point of care (POC) with a sensitivity of ≤10 IU/mL, and, results available within 2 hours. Fifty-nine consecutive HCV-patients ready for DAAs treatment were enrolled. HCV-RNA was simultaneously tested using Roche TaqMan RT-PCR (venous blood sample) and GXHVL (capillary blood collected by fingerstick), at baseline (BL), week 4 (W4) of therapy, end of therapy (EOT) and week 12 of follow-up (W12FU). Both assays de…

Malemedicine.medical_specialtyEnd of therapyFingerstickHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsInternal medicineTaqManmedicineOutpatient settingHumansHCV DAAAgedPoint of careHepatologybusiness.industryVenous blood sampleMiddle AgedViral LoadHepatitis CPoint-of-Care TestingRNA ViralFemalebusinessViral loadLiver International
researchProduct